Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
national top stories
new york top stories
biotech
boston blog main
boston top stories
fda
new york blog main
san francisco top stories
abbvie
acorda therapeutics
akcea therapeutics
alnylam pharmaceuticals
ampyra
apokyn
apomorphine
barry greene
billy dunn
biogen
boston
boston university
dalfampridine
dan ollendorf
drug prices
drug pricing
drugs
duopa
europe top stories
evrysdi
gene therapy
genentech
hereditary transthyretin amyloidosis
inbrija
inotersen
ionis pharmaceuticals
john berk
mary o'donnell
mylan
What
friday
4
×
patients
4
×
fda
new
approved
drug
medicine
acorda
admissions
admitted
ago
alnylam
analysis
annually
approve
atrophy
awaits
biological
british
called
caused
cope
crossed
daily
death
deaths
decades
decision
discovered
disease
doesn't
earlier
effect
episodes
evrysdi
findings
fingers
gets
green
help
Language
unset
Current search:
friday
×
patients
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@theverge.com
8 years ago
11,000 UK hospital deaths may be caused annually by 'the weekend effect'